PLA2G4B Antikörper (AA 514-781) (FITC)
Kurzübersicht für PLA2G4B Antikörper (AA 514-781) (FITC) (ABIN7149406)
Target
Alle PLA2G4B Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 514-781
-
Kreuzreaktivität
- Human
-
Aufreinigung
- >95%, Protein G purified
-
Immunogen
- Recombinant Human Cytosolic phospholipase A2 beta protein (514-781AA)
-
Isotyp
- IgG
-
-
-
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4 -
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C,-80 °C
-
Informationen zur Lagerung
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
-
- PLA2G4B (Phospholipase A2, Group IVB (Cytosolic) (PLA2G4B))
-
Andere Bezeichnung
- PLA2G4B
-
Hintergrund
-
Background: Calcium-dependent phospholipase A2 that selectively hydrolyzes glycerophospholipids in the sn-2 position with a preference for arachidonoyl phospholipids. Has a much weaker activity than PLA2G4A. Isoform 3 has calcium-dependent activity against palmitoyl-arachidonyl-phosphatidylethanolamine and low level lysophospholipase activity but no activity against phosphatidylcholine. Isoform 5 does have activity against phosphatidylcholine.
Aliases: PLA2G4B antibody, Cytosolic phospholipase A2 beta antibody, cPLA2-beta antibody, EC 3.1.1.4 antibody, Phospholipase A2 group IVB antibody
-
UniProt
- P0C869
-
Pathways
- ER-Nucleus Signaling, VEGF Signaling
Target
-